WO2003007881A3 - Antibodies specific for nanotubes and related methods and compositions - Google Patents

Antibodies specific for nanotubes and related methods and compositions Download PDF

Info

Publication number
WO2003007881A3
WO2003007881A3 PCT/US2002/022620 US0222620W WO03007881A3 WO 2003007881 A3 WO2003007881 A3 WO 2003007881A3 US 0222620 W US0222620 W US 0222620W WO 03007881 A3 WO03007881 A3 WO 03007881A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
nanotubes
antibodies specific
related methods
antibody
Prior art date
Application number
PCT/US2002/022620
Other languages
French (fr)
Other versions
WO2003007881A2 (en
Inventor
Bernard F Erlanger
Louis Brus
Michael P Sheetz
Original Assignee
Univ Columbia
Bernard F Erlanger
Louis Brus
Michael P Sheetz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Bernard F Erlanger, Louis Brus, Michael P Sheetz filed Critical Univ Columbia
Priority to AU2002354929A priority Critical patent/AU2002354929A1/en
Priority to US10/484,031 priority patent/US20050069947A1/en
Publication of WO2003007881A2 publication Critical patent/WO2003007881A2/en
Publication of WO2003007881A3 publication Critical patent/WO2003007881A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention provides two compositions. The first composition comprises a nanotube and at least one anti-nanotube antibody, wherein the anti-nanotube antibody is bound to the nanotube. The second composition comprises a fullerene and at least one anti-fullerene antibody, wherein the anti-fullerene antibody is bound to the fullerene. Finally, this invention provides methods and kits relating to the antibody and compositions of matter.
PCT/US2002/022620 2001-07-16 2002-07-16 Antibodies specific for nanotubes and related methods and compositions WO2003007881A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002354929A AU2002354929A1 (en) 2001-07-16 2002-07-16 Antibodies specific for nanotubes and related methods and compositions
US10/484,031 US20050069947A1 (en) 2001-07-16 2002-07-16 Antibodies specific for nanotubes and related methods and compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30592901P 2001-07-16 2001-07-16
US60/305,929 2001-07-16
US37102302P 2002-04-08 2002-04-08
US60/371,023 2002-04-08

Publications (2)

Publication Number Publication Date
WO2003007881A2 WO2003007881A2 (en) 2003-01-30
WO2003007881A3 true WO2003007881A3 (en) 2003-11-27

Family

ID=26974872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022620 WO2003007881A2 (en) 2001-07-16 2002-07-16 Antibodies specific for nanotubes and related methods and compositions

Country Status (3)

Country Link
US (2) US20030113940A1 (en)
AU (1) AU2002354929A1 (en)
WO (1) WO2003007881A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060175601A1 (en) * 2000-08-22 2006-08-10 President And Fellows Of Harvard College Nanoscale wires and related devices
CA2417992C (en) * 2000-08-22 2010-10-19 President And Fellows Of Harvard College Doped elongated semiconductors, growing such semiconductors, devices including such semiconductors and fabricating such devices
US7301199B2 (en) * 2000-08-22 2007-11-27 President And Fellows Of Harvard College Nanoscale wires and related devices
EP1342075B1 (en) * 2000-12-11 2008-09-10 President And Fellows Of Harvard College Device contaning nanosensors for detecting an analyte and its method of manufacture
US8029734B2 (en) * 2001-03-29 2011-10-04 The Board Of Trustees Of The Leland Stanford Junior University Noncovalent sidewall functionalization of carbon nanotubes
CA2516820A1 (en) * 2003-02-07 2004-11-18 Wisconsin Alumni Research Foundation Nanocylinder-modified surfaces
WO2005059508A2 (en) * 2003-12-11 2005-06-30 The Trustees Of The University Of Pennsylvania Cellular probes
CA2549117A1 (en) * 2003-12-15 2005-06-30 Nano-C, Inc. High efficiency fullerene-based radical scavengers
US20090227107A9 (en) * 2004-02-13 2009-09-10 President And Fellows Of Havard College Nanostructures Containing Metal Semiconductor Compounds
US20070264623A1 (en) * 2004-06-15 2007-11-15 President And Fellows Of Harvard College Nanosensors
US20080132584A1 (en) * 2004-12-02 2008-06-05 The Trustees Of The University Of Pennsylvania Biofunctional Nanoprobes
WO2007044034A2 (en) * 2004-12-06 2007-04-19 President And Fellows Of Harvard College Nanoscale wire-based data storage
WO2006108188A2 (en) * 2005-04-07 2006-10-12 Reveo, Inc. Probes, methods of making probes and applications of probes
WO2006116021A2 (en) * 2005-04-22 2006-11-02 Intematix Corporation Mri technique based on electron spin resonance and endohedral contrast agent
US20100227382A1 (en) 2005-05-25 2010-09-09 President And Fellows Of Harvard College Nanoscale sensors
WO2006132659A2 (en) 2005-06-06 2006-12-14 President And Fellows Of Harvard College Nanowire heterostructures
CA2655340C (en) 2006-06-12 2016-10-25 President And Fellows Of Harvard College Nanosensors and related technologies
US7768050B2 (en) * 2006-07-07 2010-08-03 The Trustees Of The University Of Pennsylvania Ferroelectric thin films
US8058640B2 (en) 2006-09-11 2011-11-15 President And Fellows Of Harvard College Branched nanoscale wires
US7968474B2 (en) 2006-11-09 2011-06-28 Nanosys, Inc. Methods for nanowire alignment and deposition
WO2008127314A1 (en) 2006-11-22 2008-10-23 President And Fellows Of Harvard College High-sensitivity nanoscale wire sensors
JP4921400B2 (en) * 2008-03-03 2012-04-25 独立行政法人科学技術振興機構 Supramolecular nanotubes with fullerenes on the inner and outer wall surfaces
JP2012528020A (en) 2009-05-26 2012-11-12 ナノシス・インク． Methods and systems for electric field deposition of nanowires and other devices
WO2011038228A1 (en) 2009-09-24 2011-03-31 President And Fellows Of Harvard College Bent nanowires and related probing of species
WO2013137854A1 (en) * 2012-03-12 2013-09-19 Empire Technology Development Llc Antibodies that bind to nanoparticles
WO2015105354A1 (en) * 2014-01-08 2015-07-16 주식회사 엘지화학 Fullerene derivatives and organic electronic device comprising fullerene derivatives
KR20150083006A (en) * 2014-01-08 2015-07-16 주식회사 엘지화학 Fullerene derivatives and organic electronic device comprising fullerene derivatives
US20180265361A1 (en) * 2015-02-18 2018-09-20 Larry Burchfield Novel Carbon Allotrope
US11002730B2 (en) * 2018-05-23 2021-05-11 International Business Machines Corporation Molecular design to suppress desorption of self-assembled monolayers
CN117330749B (en) * 2023-11-29 2024-03-08 成都信息工程大学 O-phenylenediamine composite material, detection reagent and method for detecting African swine fever

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310669A (en) * 1992-06-22 1994-05-10 The Trustees Of Dartmouth College Fullerene coated surfaces and uses thereof
WO1997032571A1 (en) * 1996-03-06 1997-09-12 Hyperion Catalysis International, Inc. Functionalized nanotubes
US5866434A (en) * 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6159742A (en) * 1998-06-05 2000-12-12 President And Fellows Of Harvard College Nanometer-scale microscopy probes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US531069A (en) * 1894-12-18 scotford
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6593137B1 (en) * 1999-08-31 2003-07-15 The Trustees Of Columbia University In The City Of New York Antibodies specific for fullerenes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310669A (en) * 1992-06-22 1994-05-10 The Trustees Of Dartmouth College Fullerene coated surfaces and uses thereof
US5866434A (en) * 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
WO1997032571A1 (en) * 1996-03-06 1997-09-12 Hyperion Catalysis International, Inc. Functionalized nanotubes
US6159742A (en) * 1998-06-05 2000-12-12 President And Fellows Of Harvard College Nanometer-scale microscopy probes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Antibodies to fullerenes and their properties", FASEB JOURNAL, vol. 12, no. 5, SUPPL. 2, 20 March 1998 (1998-03-20), pages A887, XP002933928 *
CHEN ET AL.: "Antigenicity of fullerenes: Antibodies specific for fullerenes and their characteristics", PROC. NATL. ACAD. SCI. USA, vol. 95, September 1998 (1998-09-01), pages 10809 - 10813, XP002933927 *

Also Published As

Publication number Publication date
AU2002354929A1 (en) 2003-03-03
US20050069947A1 (en) 2005-03-31
WO2003007881A2 (en) 2003-01-30
US20030113940A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
WO2003007881A3 (en) Antibodies specific for nanotubes and related methods and compositions
WO2004058820A3 (en) Single-domain-effector group and its uses
CY2019029I2 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
CY2018010I2 (en) ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2003074679A3 (en) Antibody optimization
EP1974748A3 (en) Antibodies for the diagnosis of diseases associated with fibrosis
WO2001075097A3 (en) Improvements to ribosome display
WO2005003171A3 (en) Modified antibody fragments
WO2005050171A3 (en) Methods and compositions relating to single reactive center reagents
BR0315284B1 (en) method of producing a stable aqueous silanized colloidal silica dispersion, stable aqueous silanized colloidal silica dispersion, and use of a silanized colloidal silica dispersion.
WO2002085945A3 (en) Vhh single heavy chain antibody and a method for its preparation in a mammal
WO2003048207A3 (en) Anti-dota antibody
WO2005114708A3 (en) Carbon nanotube-silicon composite structures and methods for making same
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
EP2186884A3 (en) HCV-anti-core monoclonal antibody
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
WO2002036738A3 (en) Affinity maturation by competitive selection
AU2001268232A1 (en) Compositions, methods, and kits relating to resistin-like molecules
WO2002097439A3 (en) A differential labelling method
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2006012643A3 (en) Agents with selective k-opioid receptor affinity
WO2001051651A3 (en) High expression and production of high-specific activity recombinant s-adenosyl homocysteinase (sahh) and improved assays for s-adenosylmethionine (sam)
WO2004081029A3 (en) Novel non-invasive marker for liver disease
AU2002226059A1 (en) Improved compositions and methods for producing antibodies to low molecular weight analytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10484031

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP